Therefore, in the chemotherapeutic trials conducted here, ADR conjugates were particularly good candidates for evaluation because free ADR is excluded from the brain by Pgp1 efflux activity and because ADR is completely ineffective in treating brain tumors [92] because of hindrance by the BBB. The gene discussed is CD44; the disease is brain neoplasm.